Lower riskDrug recall · FDA · Published August 10, 2023
Imprimis Moxifloxacin-Bromfenac Eye Drops Recall: Subpotent Drug Risk
Imprimis recalls 5mL eye drop bottles with subpotent Bromfenac levels. These drops may not provide proper treatment for eye infections. Stop using immediately if you have the affected lot numbers.
“Imprimis Moxifloxacin-Bromfenac Eye Drops Recall: Subpotent Drug Risk.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/33216-imprimis-moxifloxacin-bromfenac-eye-drops-recall-subpotent-drug-risk. Based on FDA recall #D-1094-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1094-2023%22&limit=1).
Imprimis NJOF, LLC voluntarily recalled Moxifloxacin - Bromfenac Sterile Ophthalmic Solution due to subpotent drug levels below specification, according to the FDA on August 10, 2023.
Lot #s: 22DEC047 exp 9/16/23, 23FEB057 exp 11/24/23
The hazard
The recall addresses subpotent drug levels, specifically Bromfenac concentrations falling below the 90.0-110.0% specification range.
Context
GovInfoNow's records show Imprimis NJOF, LLC has 13 other recalls on record since December 17, 2020. Other recent recalls of similar products include Imprimis Rx Povidone Iodine Ophthalmic Solution Recall (August 24, 2026), Apotex Brimonidine/Timolol Eye Drops Recall (March 5, 2026), and K.C. Pharmaceuticals Sterile Eye Drops AC Recall (March 3, 2026).
How to tell if you have this one
Check for the 5mL bottle labeled with the product name Moxifloxacin-Bromfenac Sterile Ophthalmic Solution 0.5%/0.075%. Look for the lot numbers 22DEC047 (expires 9/16/23) or 23FEB057 (expires 11/24/23).
Brand
Imprimis
Category
Drug
Based on the official FDA remedy
What to do — step by step
Stop Using Immediately
Discard the affected eye drops if you have the lot numbers 22DEC047 or 23FEB057.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 5 months after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-1094-2023 (August 10, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1094-2023 to see it in context.
Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.